Many of the women who are diagnosed with a very specific type of breast cancer, but one of the most frequent, They will be able to avoid undergoing chemotherapy treatment and suffer its secondary effects.ndarios.
This has been evidenced by a study promoted by the SWOG Cancer Research Network American, which has had the support of the National Cancer Institute and which has been carried out in 632 specialized centers in nine countries, including Spain. United States, Canada, Ireland, France, Mexico, Colombia, South Korea and Arabia
According to the results of this study, called RxPONDER and featured in the recently held San Antonio Breast Cancer Symposium, the world’s largest event on breast cancer, the postmenopausal women affected by the luminal subtype of breast cancer, one of the most frequent, they will be able to avoid chemotherapy treatment and undergo only hormone therapy, despite which the treatment will have the same efficacy and identical prognosis. In practice, this could benefit, in Spain alone, more than 5,000 women.
The results of this research can be applied to postmenopausal women, hormone receptor positive, epidermal growth factor receptor 2 (HER2) negative, have between 1 and 3 affected axillary nodes and a result of the so-called recurrence score (score that estimates the risk of recurrence and the probability of benefiting from chemotherapy) equal to or less than 25.
The study also showed that in the case of women who have not yet reached menopause and who are affected by this type of cancer is beneficial to undergo chemotherapy treatments.
RESULTS IN SPAIN
In Spain, the study was carried out with more than 5,000 patients who were undergoing treatment in 21 hospitals throughout the country and who were compliant were included in the group under study. Until now, this type of cancer is treated with chemotherapy and hormone therapy.
The trial conducted on Spanish patients also concluded that the cure prognosis of this type of cancer in all groups of patients is excellent, despite having affected lymph nodes, and the percentage of those that did not have recurrence for five years exceeds 90%.
–
–
